Cargando…

Mycobacterial drug discovery

Mycobacterium tuberculosis is the causative pathogen of the pulmonary disease tuberculosis. Despite the availability of effective treatment programs, there is a global pursuit of new anti-tubercular agents to respond to the developing threat of drug resistance, in addition to reducing the extensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Abrahams, Katherine A., Besra, Gurdyal S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126887/
https://www.ncbi.nlm.nih.gov/pubmed/34085044
http://dx.doi.org/10.1039/d0md00261e
_version_ 1783693848017371136
author Abrahams, Katherine A.
Besra, Gurdyal S.
author_facet Abrahams, Katherine A.
Besra, Gurdyal S.
author_sort Abrahams, Katherine A.
collection PubMed
description Mycobacterium tuberculosis is the causative pathogen of the pulmonary disease tuberculosis. Despite the availability of effective treatment programs, there is a global pursuit of new anti-tubercular agents to respond to the developing threat of drug resistance, in addition to reducing the extensive duration of chemotherapy and any associated toxicity. The route to mycobacterial drug discovery can be considered from two directions: target-to-drug and drug-to-target. The former approach uses conventional methods including biochemical assays along with innovative computational screens, but is yet to yield any drug candidates to the clinic, with a high attrition rate owing to lack of whole cell activity. In the latter approach, compound libraries are screened for efficacy against the bacilli or model organisms, ensuring whole cell activity, but here subsequent target identification is the rate-limiting step. Advances in a variety of scientific fields have enabled the amalgamation of aspects of both approaches in the development of novel drug discovery tools, which are now primed to accelerate the discovery of novel hits and leads with known targets and whole cell activity. This review discusses these traditional and innovative techniques, which are widely used in the quest for new anti-tubercular compounds.
format Online
Article
Text
id pubmed-8126887
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher RSC
record_format MEDLINE/PubMed
spelling pubmed-81268872021-06-02 Mycobacterial drug discovery Abrahams, Katherine A. Besra, Gurdyal S. RSC Med Chem Chemistry Mycobacterium tuberculosis is the causative pathogen of the pulmonary disease tuberculosis. Despite the availability of effective treatment programs, there is a global pursuit of new anti-tubercular agents to respond to the developing threat of drug resistance, in addition to reducing the extensive duration of chemotherapy and any associated toxicity. The route to mycobacterial drug discovery can be considered from two directions: target-to-drug and drug-to-target. The former approach uses conventional methods including biochemical assays along with innovative computational screens, but is yet to yield any drug candidates to the clinic, with a high attrition rate owing to lack of whole cell activity. In the latter approach, compound libraries are screened for efficacy against the bacilli or model organisms, ensuring whole cell activity, but here subsequent target identification is the rate-limiting step. Advances in a variety of scientific fields have enabled the amalgamation of aspects of both approaches in the development of novel drug discovery tools, which are now primed to accelerate the discovery of novel hits and leads with known targets and whole cell activity. This review discusses these traditional and innovative techniques, which are widely used in the quest for new anti-tubercular compounds. RSC 2020-11-06 /pmc/articles/PMC8126887/ /pubmed/34085044 http://dx.doi.org/10.1039/d0md00261e Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Abrahams, Katherine A.
Besra, Gurdyal S.
Mycobacterial drug discovery
title Mycobacterial drug discovery
title_full Mycobacterial drug discovery
title_fullStr Mycobacterial drug discovery
title_full_unstemmed Mycobacterial drug discovery
title_short Mycobacterial drug discovery
title_sort mycobacterial drug discovery
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126887/
https://www.ncbi.nlm.nih.gov/pubmed/34085044
http://dx.doi.org/10.1039/d0md00261e
work_keys_str_mv AT abrahamskatherinea mycobacterialdrugdiscovery
AT besragurdyals mycobacterialdrugdiscovery